JNJ or MRK: One Dividend Is Built to Last, One Faces a Reckoning - 24/7 Wall St.
JNJ or MRK: One Dividend Is Built to Last, One Faces a Reckoning 24/7 Wall St.
Covered in this story
What has happened since
- Johnson & Johnson is up 0.5% since this was published, 6 days ago.
- Merck & Co. is down 0.1% since this was published, 6 days ago.
Price move measured from the close nearest publication to the latest quote.
Analyst targets on Johnson & Johnson
- RBC Capital Markets: $255 → $290 by Oct 2027 · Outperform via Investing.com
- Bank of America: $265 → $278 by Sep 2027 · Neutral via AOL.com
- Raymond James: $254 → $280 by Aug 2027 · Outperform via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $JNJ yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Johnson & Johnson →Dalsna Finance is currently tracking 44 stories mentioning Johnson & Johnson, the earliest published 11 Jun 2026.
Summary aggregated from Google News's public RSS feed. The full reporting belongs to Google News — please read it on their site.